The market leader in obesity shots, Lilly hasn’t made a major dent in the pill market yet.

With a share price of $1,182, Eli Lilly (LLY) is positioned for about 76% potential growth over the next three years in a ...

FDA grants full approval to Eli Lilly's selpercatinib (Retevmo) for a wider group of adult and pediatric patients with RET ...

Eyes are on the rollout of Lilly's new weight loss pill.

Dave Ricks steered the 150-year-old drug giant to a $1 trillion market cap. Can he defeat pharma’s boom and bust cycle?

SpaceX recently completed a record IPO.

Eli Lilly has whipsawed shareholders in 2026, but one under-the-radar catalyst in its pipeline could change the trajectory ...

A U.S. appeals court on Monday revived a lawsuit brought by generic drugmaker Teva Pharmaceuticals that accuses Eli Lilly of ...

The pharma titan is expanding into new markets.

Eli Lilly's new top dealmaker explains how the company changed its approach to M&A now that it's the most valuable pharmaceutical company in the world.

In the world of big pharma, one company is both the star performer and the most expensive name on the marquee, forcing ...

The pharmaceutical industry is entering a new era where biology and artificial intelligence are converging. Drug discovery, ...